Trials / Terminated
TerminatedNCT02499315
Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- 25 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to find out if AMG 357 is safe and tolerated by women with Rhematoid Arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 357 | Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets. |
| DRUG | Placebo | Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets. |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2015-07-16
- Last updated
- 2016-05-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02499315. Inclusion in this directory is not an endorsement.